Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:FOLD NASDAQ:GERN NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$26.55-0.2%$29.09$25.56▼$36.45$4.39B0.472.22 million shs1.12 million shsFOLDAmicus Therapeutics$6.93-0.9%$6.10$5.51▼$12.65$2.15B0.534.36 million shs3.93 million shsGERNGeron$1.39+15.4%$1.40$1.09▼$4.84$764.30M0.739.57 million shs28.38 million shsLGNDLigand Pharmaceuticals$142.40+5.4%$120.37$92.04▼$143.79$2.61B0.85196,447 shs300,453 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-0.19%-4.94%-9.17%-12.65%-3.45%FOLDAmicus Therapeutics-0.86%+13.05%+14.55%+13.98%-30.28%GERNGeron+15.42%+25.91%+1.09%+9.49%-69.89%LGNDLigand Pharmaceuticals+5.36%+5.30%+25.18%+38.91%+43.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.7677 of 5 stars4.41.00.04.23.92.51.9FOLDAmicus Therapeutics4.1381 of 5 stars3.41.00.04.33.60.01.9GERNGeron3.1147 of 5 stars3.31.00.01.32.31.70.6LGNDLigand Pharmaceuticals4.198 of 5 stars2.51.00.04.43.33.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.83Moderate Buy$41.0854.74% UpsideFOLDAmicus Therapeutics 2.80Moderate Buy$16.22134.09% UpsideGERNGeron 2.60Moderate Buy$4.61232.93% UpsideLGNDLigand Pharmaceuticals 3.00Buy$150.005.34% UpsideCurrent Analyst Ratings BreakdownLatest GERN, ALKS, LGND, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$40.00 ➝ $42.007/30/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$145.00 ➝ $162.007/29/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.007/21/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$46.007/21/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.007/17/2025FOLDAmicus TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight7/15/2025ALKSAlkermesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$43.007/10/2025GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$1.006/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.005/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B2.81$2.65 per share10.03$9.84 per share2.70FOLDAmicus Therapeutics$528.29M4.04N/AN/A$0.66 per share10.50GERNGeron$76.99M11.46N/AN/A$0.46 per share3.01LGNDLigand Pharmaceuticals$167.13M16.44$1.69 per share84.11$43.95 per share3.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0812.7619.381.5223.15%24.86%17.14%10/23/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.12N/A16.12N/A-6.67%-5.07%-1.23%N/AGERNGeron-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%N/ALGNDLigand Pharmaceuticals-$4.03M-$7.12N/A38.38N/A-73.07%-7.83%-6.92%8/7/2025 (Estimated)Latest GERN, ALKS, LGND, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54N/AN/AN/A$43.87 millionN/A8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 million5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/7/2025Q1 2025GERNGeron-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85FOLDAmicus Therapeutics1.923.212.29GERNGeron0.447.876.97LGNDLigand PharmaceuticalsN/A5.275.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%FOLDAmicus TherapeuticsN/AGERNGeron73.71%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%FOLDAmicus Therapeutics2.20%GERNGeron7.42%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableFOLDAmicus Therapeutics480308.24 million301.46 millionOptionableGERNGeron229636.92 million589.66 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableGERN, ALKS, LGND, and FOLD HeadlinesRecent News About These CompaniesJohn W. Kozarich Sells 467 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockAugust 6 at 8:24 PM | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich Sells 467 SharesAugust 6 at 6:14 AM | insidertrades.comLigand Pharmaceuticals (LGND) to Release Earnings on ThursdayAugust 5 at 2:15 AM | americanbankingnews.com2,519 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Bought by Pacer Advisors Inc.August 2, 2025 | marketbeat.comOppenheimer Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) StockJuly 31, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $2.22 Million in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 31, 2025 | marketbeat.comLigand Pharmaceuticals (LGND) Expected to Announce Quarterly Earnings on ThursdayJuly 31, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of "Buy" by AnalystsJuly 30, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Holdings Decreased by Essex Investment Management Co. LLCJuly 29, 2025 | marketbeat.comVictory Capital Management Inc. Has $2.91 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 29, 2025 | marketbeat.comEnvestnet Asset Management Inc. Sells 60,587 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 28, 2025 | marketbeat.comLigand Pharmaceuticals Inc (LGND) Announces Upcoming Q2 2025 Financial Results Release | LGND ...July 24, 2025 | gurufocus.comLigand to Report Second Quarter 2025 Financial Results on August 7, 2025July 24, 2025 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High - Time to Buy?July 22, 2025 | marketbeat.comBank of New York Mellon Corp Sells 3,421 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 21, 2025 | marketbeat.comNew York State Common Retirement Fund Increases Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 19, 2025 | marketbeat.comJackson Creek Investment Advisors LLC Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 18, 2025 | marketbeat.comStocks Showing Rising Market Leadership: Ligand Pharmaceuticals Earns 84 RS RatingJuly 18, 2025 | msn.comLigand Pharmaceuticals Stock Earns 84 RS RatingJuly 17, 2025 | msn.comJ&J boosts full-year outlook on forex tailwinds and operational performanceJuly 16, 2025 | msn.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 52-Week High - Still a Buy?July 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGERN, ALKS, LGND, and FOLD Company DescriptionsAlkermes NASDAQ:ALKS$26.55 -0.05 (-0.19%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$26.56 +0.00 (+0.02%) As of 08/6/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Amicus Therapeutics NASDAQ:FOLD$6.93 -0.06 (-0.86%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$7.04 +0.11 (+1.52%) As of 08/6/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Geron NASDAQ:GERN$1.38 +0.19 (+15.42%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 08/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Ligand Pharmaceuticals NASDAQ:LGND$142.40 +7.25 (+5.36%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$147.74 +5.34 (+3.75%) As of 08/6/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
